Table 1.
Author | Country | Study Design | Condition | N | Gender | Age | Criteria |
---|---|---|---|---|---|---|---|
Younger 200917 | USA | Placebo-controlled, single-blind, crossover, pilot study | Fibromyalgia | 10 | Female | 22–55 | ACR 1990 |
Ramanathan 201218 | USA | Case report | Fibromyalgia | 1 | Male | 37 | ACR 1990 |
Younger 201319 | USA | Randomized placebo-controlled crossover double-blind study | Fibromyalgia | 31 | Female | 23–65 | ACR 1990 |
Parkitny 201720 | USA | Single-blind, crossover study | Fibromyalgia | 8 | Female | 31–63 | ACR 2010 |
Metyas 201821 | USA | Two small prospective pilot open label studies | Fibromyalgia | 25 | 24 Female +1male | 30–75 | ACR 1990 |
Oaks 201822 | USA | Case series | Opioid-Induced Hyperalgesia and Fibromyalgia | 254(217 OIH & 37 FM) | 152 Female & 102 Male | 14–89 | ACR 1990 |
Bruun-Plesner 202023 | Denmark | Prospective dose–response study | Fibromyalgia | 25 | Female | 27–59 | ACR 1990 and ACR 2011 |
Jackson 202124 | USA | Case series | Opioid Induced Hyperalgesia and Fibromyalgia | 76(55 OIH, and 21 FM) | 19 Female +2 Male | 37–50 | ACR 1990 |
Siembida 202216 | USA | Case report | Depression in Fibromyalgia | 1 | Male | 60 | ACR 1990 |
Note: ACR, American College of Rheumatology; OIH, opioid-induced hyperalgesia; FM, fibromyalgia.